Tirzepatide. Dual action.
A compounded dual GIP/GLP-1 receptor agonist prescribed by Aryo physicians as part of a personalized weight management program.
$399 for 3 monthsincludes physician visit, medication, supplies & shipping
Why two pathways matter
For members who plateau on semaglutide, or who need an alternative option toward a metabolic target, tirzepatide is often the next step.
Considerations
As with semaglutide, tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2, and in patients with a history of pancreatitis. It is not for use during pregnancy. Common side effects — nausea, GI upset, fatigue — are usually mild and resolve as your body adjusts.
Tirzepatide is a prescription medication. Results in clinical trials required combined therapy with diet and physical activity. Individual results vary. Discuss risks and benefits with your Aryo clinician.